Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL) will release its fourth quarter and fiscal year 2020 financial results and a business update on March 18, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) will release its fourth quarter and fiscal year 2020 financial results and a business update on March 18, 2021. The company focuses on improving lives through its ARCUS® genome editing platform, which enables the development of CAR T immunotherapy clinical candidates and gene correction therapies. These advancements aim to address genetic and infectious diseases lacking adequate treatment options. For more information, visit www.precisionbiosciences.com.
Positive
- Precision BioSciences is advancing its proprietary ARCUS genome editing platform.
- The upcoming financial results may provide insights into the company's growth.
- ARCUS enables development of novel CAR T immunotherapy candidates.
Negative
- None.
Details
News Market Reaction – DTIL
The recorded move for DTIL in the trading session of this news was -2.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Investor Contact:
Alex Kelly
Interim Chief Financial Officer
Alex.Kelly@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.